Early detection of solid malignancies remains a major challenge because many cancers produce few or nonspecific symptoms during their initial stages. Conventional diagnostic approaches, including imaging and tissue biopsy, remain fundamental for establishing the presence and histological characteristics of cancer, but they may be invasive, technically demanding, or unsuitable for repeated sampling. Liquid biopsy offers an alternative source of tumor-associated molecular information through analysis of blood-derived components. ctDNA is particularly valuable because tumor-specific mutations, copy-number alterations, methylation patterns, and other molecular abnormalities can potentially be detected in plasma. The clinical significance of ctDNA is especially promising in cancers where early diagnosis is difficult and tumor-derived DNA levels are low. At the same time, a negative liquid-biopsy result cannot necessarily exclude early malignancy because insufficient ctDNA shedding may produce false-negative findings. Comparative evaluation of diagnostic accuracy is therefore essential before routine implementation of ctDNA-based testing in early cancer detection.
To evaluate the diagnostic potential of liquid biopsy and ctDNA analysis for early detection of solid malignancies and to compare their diagnostic performance with established clinical, imaging, and tissue-based methods.
The diagnostic framework includes patients with suspected or newly diagnosed solid malignancies and appropriate nonmalignant comparison groups. Peripheral blood samples are collected using standardized preanalytical procedures, followed by plasma separation and extraction of cell-free DNA. ctDNA is analyzed using molecular techniques such as digital polymerase chain reaction, targeted next-generation sequencing, or methylation-based assays, depending on the suspected tumor type and molecular target. Diagnostic performance is assessed using sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve. The results of liquid-biopsy testing are compared with reference standards, including histopathological examination and clinically appropriate imaging. Particular attention is given to tumor stage, tumor type, ctDNA concentration, molecular alterations detected, and the frequency of false-positive and false-negative results. The potential influence of preanalytical variables and assay sensitivity on diagnostic accuracy is also considered.
ctDNA analysis demonstrates considerable potential for identifying molecular signals associated with solid malignancies, particularly when highly sensitive analytical methods are used. The diagnostic performance of liquid biopsy varies substantially according to cancer type and stage. In advanced tumors, increased tumor shedding generally provides a greater quantity of detectable ctDNA, whereas early-stage tumors may release very small amounts into the circulation. This biological limitation is one of the major challenges for early cancer detection. Highly sensitive methods, including digital PCR and advanced sequencing technologies, can improve detection of low-frequency molecular alterations. Methylation-based approaches may provide additional diagnostic information because epigenetic patterns can reflect tissue-specific malignant processes. Compared with conventional serum tumor biomarkers, ctDNA analysis can provide more tumor-specific molecular information in appropriately selected settings. Nevertheless, a negative ctDNA result does not exclude cancer, particularly when tumor burden is low. Therefore, liquid biopsy demonstrates the greatest clinical value when incorporated into a multimodal diagnostic pathway rather than used as a stand-alone test.
Liquid biopsy and ctDNA analysis represent promising developments in minimally invasive cancer diagnostics. Their ability to detect tumor-associated genetic and epigenetic alterations from blood provides opportunities for earlier molecular characterization of solid malignancies and repeated disease assessment. Diagnostic accuracy depends strongly on tumor type, disease stage, ctDNA shedding, assay sensitivity, and preanalytical standardization. Although ctDNA-based testing may complement conventional biomarkers and imaging, tissue diagnosis remains essential in many clinical situations. Future improvements in ultra-sensitive sequencing, methylation analysis, fragmentomics, and multimodal artificial-intelligence-assisted algorithms may increase the sensitivity of liquid biopsy for early-stage disease. Before widespread clinical adoption for population screening, robust prospective validation and standardized testing strategies are required.
1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 2014;6(224):224ra24.
2. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017;17:223–238.
3. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics. 2019;20:71–88.
4. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930.
5. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385–389.
6. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Annals of Oncology. 2021;32(9):1167–1177.
7. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nature Reviews Clinical Oncology. 2019;16:409–424.
8. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nature Reviews Clinical Oncology. 2021;18:297–312.
9. National Cancer Institute. Liquid Biopsy and Circulating Tumor DNA in Cancer Research. National Institutes of Health.
10. Med1.uz. Liquid biopsy and molecular biomarkers in modern cancer diagnostics. Medical information resource. https://med1.uz/